On August 4, 2021, Wuhan Hiteck Biological Pharma Co., Ltd. closed the transaction. The company issued 18,749,125 shares at a price of CNY for gross proceeds of CNY 32 each for gross proceeds of CNY 599,972,000. The transaction included participation from Chen Ya for 1,250,000 shares, UBS Group AG for 750,000 shares, China Asset Management Co., Ltd. for 1,406,250 shares, Hunan Ruishi Private Equity Fund Management Co., Ltd. for 829,062 shares, Shenzhen Qianhai Eagle Fund Management Co., Ltd. for 1,067,118 shares, Liu Xia for 625,000 shares, Gao Yuan for 1,250,000 shares, Shen Xianglong for 3,125,000 shares, Yu Jingwen for 875,000 shares, Chen Chuanxing for 2,375,000 shares, Jingmen High Tech Industrial Investment Co., Ltd. for 937,500 shares, Nanhua Fund Management Co., Ltd. for 656,250 shares, Shanghai Boshen Investment Center (Limited Partnership) for 625,000 shares, Caitong Fund Management Co., Ltd. for 765,625 shares, Changsha Shengnong Private Equity Fund Partnership Enterprise (L.P.), a fund managed by Changsha Hi-tech Weide Fund Management Co., Ltd. for 656,250 shares, You Xinnong for 906,250 shares, and Wuhan Economic Development Financial Development Co., Ltd. for 649,820 shares.

The company paid CNY 11,877,590.53 as issue expenses and received net proceeds of CNY 599,972,000.